新诊断多发性骨髓瘤患者接受四联方案后疾病进展的后续治疗与结局
该研究分析了274例接受四联方案联合自体干细胞移植的新诊断多发性骨髓瘤患者,中位随访21.3个月后,20例在四联方案开始后18个月内进展,21例在18个月及以上进展。所有患者均接受后续抗骨髓瘤治疗,早期进展组对后续治疗缓解率26.3%、中位无进展生存期2.5个月,晚期进展组分别为52.6%和7.0个月。
要点
- 四联方案后18个月内进展者后续治疗缓解率26.3%,中位无进展生存期2.5个月。
- 四联方案后18个月及以上进展者后续治疗缓解率52.6%,中位无进展生存期7.0个月。
- 9例(22.0%)将T细胞重定向治疗作为下一线治疗,21例(51.2%)在治疗过程中曾使用。
核心结论
- 对于四联方案治疗失败的患者,应致力于早期使用具有新作用机制的疗法。
研究设计与样本
- 研究分析了274例连续接受四联方案联合自体干细胞移植的新诊断多发性骨髓瘤患者。
- 中位随访21.3个月后,20例在四联方案开始后18个月内疾病进展,21例在18个月及以上进展。
主要发现
- 所有患者均接受了后续抗骨髓瘤治疗,其中38例评估了缓解。
- 9例(22.0%)将T细胞重定向治疗作为下一线治疗,21例(51.2%)在治疗过程中曾使用。
- 四联方案开始后18个月内进展者的后续治疗缓解率为26.3%,18个月及以上进展者为52.6%。
- 18个月内进展者后续治疗的中位无进展生存期为2.5个月(95% CI 1.5-3.4),18个月及以上进展者为7.0个月(95% CI 3.6-10.5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The combination of anti-CD38 monoclonal antibodies to a proteasome inhibitor, an immunomodulatory agent and dexamethasone (quadruplet-QUAD) in sequence with autologous stem cell transplantation (ASCT) leads to deep and durable responses in newly diagnosed multiple myeloma (NDMM). Disease progression in the first year post-QUADs is uncommon. We analysed 274 consecutive NDMM patients treated with QUADs + ASCT. After a median follow-up of 21.3 months, 20 patients had disease progression <18 months and 21 had progression ≥18 months after the onset of a QUAD regimen. All patients received subsequent anti-MM therapy, and 38 were evaluated for response. Nine (22.0%) received T-cell redirecting therapy as the next treatment, and 21 (51.2%) at some point in the treatment course. Response to next therapy was 26.3% for patients with progression <18 months and 52.6% for those with progression ≥18 months after the onset of a QUAD regimen. Median PFS on the next therapy was 2.5 months (95% CI 1.5-3.4) for those with progression <18 months and 7.0 months (95% CI 3.6-10.5) for those with progression ≥18 months. Efforts should focus on the early deployment of therapies with new mechanism of action for patients experiencing treatment failure after QUADs.
引用
- Ravi G, Bal S, Joiner L, et al. Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations. Br J Haematol. 2024. PMID: 38291707. doi:10.1111/bjh.19303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。